Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Trastuzumab without an anthracycline: better for early breast cancer
Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. :
Access to resources
Recommend
Diastolic dysfunction common among breast cancer patients receiving anthracycline
Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. :
Switch to anastrozole benefits QOL in breast cancer
Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. :
Benefits of intensive chemotherapy in breast cancer independent of age
Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. :
Fulvestrant: benefits at acceptable costs in advanced breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. :